--- title: "國家知識產權局副局長盧鵬起會見瑞士羅氏集團董事會主席" description: "中國國家知識產權局副局長盧鵬起近日會見瑞士羅氏集團董事會主席施萬，強調知識產權保護對營商環境的重要性，承諾對內外資企業一視同仁的保護。施萬指出，知識產權是創新藥企的核心競爭力，羅氏將在中國加大研發投入，推動本土醫藥創新成果的全球化。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/261886739.md" published_at: "2025-10-20T12:37:40.000Z" --- # 國家知識產權局副局長盧鵬起會見瑞士羅氏集團董事會主席 > 中國國家知識產權局副局長盧鵬起近日會見瑞士羅氏集團董事會主席施萬，強調知識產權保護對營商環境的重要性，承諾對內外資企業一視同仁的保護。施萬指出，知識產權是創新藥企的核心競爭力，羅氏將在中國加大研發投入，推動本土醫藥創新成果的全球化。 近日，中國國家知識產權局副局長盧鵬起在京會見來訪的瑞士羅氏集團董事會主席施萬一行。盧鵬起表示，近年來，知識產權保護作為營商環境的一項重要內容，日益受到中外企業的關注。中國國家知識產權局始終堅持對內外資企業的知識產權一視同仁、依法同等保護，切實維護外商投資者合法權益。未來，中國國家知識產權局將繼續秉持積極開放的態度，與各國權利人和利益相關方保持良好的交流。施萬表示，知識產權是創新藥企業生存與發展的核心競爭力。在中國不斷完善的知識產權保護體系支撐下，越來越多的跨國製藥企業對中國市場充滿信心，不斷深化本土化戰略佈局。羅氏集團將持續擴大在中國的研發投入，積極推動源自中國的醫藥創新成果惠及全球。 ### Related Stocks - [RHHBY.US - 羅氏(ADR)](https://longbridge.com/zh-HK/quote/RHHBY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy | Genentech, part of the Roche Group, announced positive Phase III results for Gazyva in treating primary membranous nephr | [Link](https://longbridge.com/zh-HK/news/276037337.md) | | Roche Appoints Mark Dawson As New Head Of Roche Pharma Research And Early Development | Roche Holding AG :ROCHE HOLDING AG - APPOINTMENT OF MARK DAWSON, M.D., PH.D., AS NEW HEAD OF ROCHE PHARMA RESEARCH AND E | [Link](https://longbridge.com/zh-HK/news/276097246.md) | | Roche Announces Filing Acceptance Of New Drug Application For Giredestrant | Roche has announced that the FDA has accepted its New Drug Application for giredestrant, an investigational oral therapy | [Link](https://longbridge.com/zh-HK/news/276417142.md) | | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | [Link](https://longbridge.com/zh-HK/news/276037536.md) | | Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/zh-HK/news/276037735.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。